Active Vitamin D analog and SARS-CoV-2 IgG after BNT162b2 vaccination in patients with hemodialysis

Abstract

Vaccination is the effective strategy for coronavirus disease 2019 (COVID-19). However, few studies have investigated the association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin (Ig)G and vitamin D. This study aimed to investigate the association between SARS-CoV-2 IgG and active vitamin D analogs in hemodialysis patients. Blood samples were collected four times: before vaccination and 30, 60, and 90 days after vaccination. We analyzed patients who were supposed to receive a third vaccination, BNT162b2 (Pfizer©). A total of 418 patients were enrolled. The mean age was 71.1 ± 12 years. Almost two thirds of the patients were prescribed active vitamin D analogs. The distribution of SARS-CoV-2 IgG before vaccination was 235 (93–454) AU/ml. The changes in the IgG after vaccination were 15582 (7233–36445) AU/ml at 30 days, 13184 (5910–30529) AU/ml at 60 days, and 10239 (4566–24971) AU/ml at 90 days. The SARS-CoV-2 IgG level of patients with active vitamin D analog use was higher in all periods. After multiple regression analyses, active vitamin D analog use was found to be associated with higher SARS-CoV-2 IgG levels from pre-vaccination to 90 days post-vaccination. This study showed an association between higher SARS-CoV-2 IgG and active vitamin D analog in hemodialysis patients.